摘要
目前,新医改政策不断深入,医药企业市场环境波动,因此必须加速医药企业的改革与发展。同时在新冠肺炎疫情的影响下,医药产业的供应链整体发展受到一定影响,促使医药企业在产品结构、产品研发、销售模式等方面进行变革。本文基于评价指标因子分析概述,以A股上市超过5年的40家医药企业为研究对象,对其2017-2020年的供应链可靠性、供应链应变能力、供应链质量三大方面10个指标进行分析。结果表明:40家医药公司的供应链可靠性不高,供应链应变能力虽有所提升,但仍需增强,供应链质量与供应链的创新发展能力有所提升。结合医药产业相关政策和发展契机,建议医药企业实行“两票制”供应链模式,建立智能化供应链体系,开拓电子商务市场和国际市场,从而实现医药企业的创新和可持续发展。
At present,with the deepening of the new medical reform policy and the fluctuation of the market environment of pharmaceutical enterprises,it is necessary to accelerate the reform and development of pharmaceutical enterprises.At the same time,under the infl uence of the Covid-19 epidemic,the overall development of the supply chain of the pharmaceutical industry has been affected to a certain extent,prompting pharmaceutical companies to make changes in product structure,product research and development,and sales models.Based on the overview of factor analysis of evaluation indicators,this paper takes 40 pharmaceutical enterprises listed on A-share market for more than five years as the research object,and analyzes 10 indicators of supply chain reliability,supply chain adaptability and supply chain quality from 2017 to 2020.The results show that the supply chain reliability of the 40 pharmaceutical companies is not high,the strain capacity of the supply chain has been improved,but it still needs to be enhanced,and the quality of the supply chain and the innovation and development ability of the supply chain have been improved.Combined with the related policies and development opportunities of the pharmaceutical industry,it is suggested that pharmaceutical enterprises implement the"two-invoice system"supply chain mode,establish an intelligent supply chain system,and explore the e-commerce market and international market,so as to realize the innovation and sustainable development of pharmaceutical enterprises.
作者
陈昕玥
CHEN Xinyue(Business School of Zhengzhou University)
出处
《中国商论》
2021年第10期126-128,共3页
China Journal of Commerce
关键词
评价指标
因子分析
供应链模式
医药企业
evaluation index
factor analysis
supply chain model
pharmaceutical enterprise
